EURONEXT-AMS$PHAR
Pharming Group NV · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Headline financials
Revenue & EPS history
Pharming Group NV · Revenue · Quarterly
€46.6M
Q1 2022+7%vs Q1 2021
Revenue by segment
Pharming Group NV · €97.3M total across 2 segments · Q3 2025
- RUCONEST€82.2M—84.5%
- Joenja (leniolisib)€15.1M—15.5%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q1 2022
-3.1%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-1.0%
Avg return
30 days after
38%
6 / 16 earnings
Positive
+12.5%
Q2 2022
Best reaction
-26.8%
Q4 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -26.8% | -93.2% | -93.1% | |
| Q3 2025 | +11.5% | +19.8% | +27.1% | |
| Q2 2024 | -8.4% | -2.9% | -7.7% | |
| Q1 2024 | -1.7% | -3.3% | -12.6% | |
| Q4 2023 | -1.7% | -1.0% | -5.2% | |
| Q3 2023 | +5.0% | +14.0% | +12.0% | |
| Q2 2023 | +4.2% | -0.5% | -1.4% | |
| Q1 2023 | -20.4% | -7.7% | -4.8% | |
| Q4 2022 | -1.6% | -14.2% | -6.2% | |
| Q3 2022 | +0.0% | +24.3% | +28.2% | |
| Q2 2022 | +12.5% | +29.6% | +59.2% | |
| Q1 2022 | +3.8% | +7.7% | +7.9% | |
| Q4 2021 | +1.3% | -2.7% | +5.8% | |
| Q3 2021 | -12.6% | -7.5% | -13.6% | |
| Q2 2021 | -6.8% | -8.8% | -4.0% | |
| Q1 2021 | -8.4% | -6.9% | -7.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro